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Abstract
The decision to treat a cervical squamous intraepithelial lesion (SIL) by loop electro-
surgical excision procedure (LEEP) relies heavily on a colposcopy-directed biopsy 
showing high-grade (H)SIL. Diagnosis is often supported by p16, an immunohisto-
chemical (IHC) biomarker of high-risk (hr)HPV E7 gene activity. Additional poten-
tial markers include methylation of tumor suppressor genes FAM19A4/miR124-2 in 
cervical cytology for advanced transforming HSIL and the IHC marker HPV E4 for 
productive, potentially regressing lesions. In 318 women referred for colposcopy, 
we investigated the relationship between staining patterns of p16 and E4 IHC in the 
worst biopsy, and the relation of these to FAM19A4/miR124-2 methylation status in 
cytology. E4-positive staining decreased with increasing SIL/CIN grade from 41% 
in LSIL to 3% in HSIL/CIN3. E4 positivity increased with grade of p16 when p16 
expression was limited to the lower two third of the epithelium (r = 0.378), but fell 
with expression over. Loss of E4 expression in the worst lesion was associated with 
the methylation of FAM19A4/miR124-2. We also examined whether these biomark-
ers can predict the histological outcome of the LEEP biopsy in a subgroup of 119 
who underwent LEEP treatment. About 85% of women with ≥lower two third p16 
staining/E4-negative HSIL biopsies and 65% with limited p16 staining/E4-positive 
HSIL biopsies had ≥HSIL in the LEEP specimen (P = .025). p16 expression in a 
biopsy is related both to viral production and transformation, while decreased E4 ex-
pression relates to methylation, indicating advanced HSIL. p16 expression in ≥2/3 of 
the epithelium and absent E4 indicate likely HSIL on a subsequent LEEP specimen.
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1 |  INTRODUCTION
In cervical cancer (CC) prevention, women with an abnormal 
screening result are subjected to colposcopy to detect of high-
grade squamous intraepithelial lesions/cervical intraepithelial 
neoplasia grades 2 and 3 (HSIL/CIN2-3), or CC. Since his-
tological diagnosis of HSIL/CIN2-3 is the basis for surgical 
treatment, accuracy of diagnosis is key. However, hematox-
ylin and eosin stain (H&E) diagnosis is subjective and sub-
stantial interobserver and intra-observer variability has been 
reported.1 Previous reports have shown that HSIL/CIN3 is 
more reproducible, but important variation exists in the diag-
nosis of HSIL/CIN2. This diagnosis includes both productive 
lesions that might regress and advanced transforming lesions 
that require treatment and can result in overtreatment.2-4
The use of biomarkers, whose results are unambiguous and 
reproducible, may provide a solution. Immunohistochemical 
(IHC) staining with p16, single or in combination with the 
proliferation marker Ki-67, has been identified as a valuable 
marker in diagnosis of  ≥HSIL/CIN2.5 p16 is a surrogate 
marker of the cell cycle deregulation by the high-risk human 
papillomavirus (hrHPV) E7 gene. The HPV-encoded marker 
panE4 is a novel marker for initiation of the viral produc-
tive phase and hence, completion of the papillomavirus life 
cycle.6 It is expressed in productive HPV infection in differ-
entiated, mature epithelial cells.7-9 HSIL/CIN3 is almost al-
ways negative for E4, while HSIL/CIN2 and LSIL/CIN1 can 
be either E4-positive or negative.7,9 Current SIL/CIN classifi-
cations do not discriminate between different biomarker pat-
terns corresponding to productive or transforming infection. 
Grading patterns of expression of biomarkers such as E4 and 
p16 might play an important role in predicting progression of 
a lesion, deciding treatment and might reduce the overtreat-
ment of productive lesions that can regress.
Hypermethylation of the CpG islands in promotor regions 
of several tumor suppressor genes is extremely high in CC 10 
and has been linked to the duration of hrHPV infection and 
the severity of the underlying neoplastic lesion.11 The combi-
nation of FAM19A4 and miR124-2 shows particularly high 
levels of positivity in women with CC and high-grade lesions 
with a longer duration of a preceding hrHPV infection.12 
Lesions with a cancer-like methylation pattern have been de-
fined as “advanced” SIL/CIN lesions. The relation between 
hypermethylation detected on cytology sample, and p16 and 
E4 expression on biopsy has not previously been studied in 
a population undergoing routine colposcopy for an abnormal 
screening result.
This study aims to describe the relationships between the 
immunohistochemical expression patterns of markers p16 
and HPV E4 in hrHPV-positive colposcopy-directed cervi-
cal biopsy, and also the relationship of these to methylation 
markers FAM19A4/miR124-2 in cervical cytology sam-
ples of women referred to a colposcopy due to an abnormal 
screening test. In addition, we studied if biomarkers p16/
E4 on biopsy and methylation on cytology can predict the 
histological outcome on loop electrosurgical excision pro-
cedure (LEEP) in a subgroup of 119 who underwent LEEP 
treatment.
2 |  METHODS
2.1 | Population
The EVAH is a follow-up study of women referred to the col-
poscopy clinic of Hospital Clínic, Barcelona, Spain because of 
abnormal cytology (≥ASC-US).13 At colposcopy, women had 
a physician-taken cervical cytology sample and 1-4 colpos-
copy-directed biopsies. Women were treated by LEEP when a 
HSIL/CIN2-3 diagnosis was found on biopsy, when underly-
ing HSIL/CIN2-3 was expected on colposcopic impression, 
or when there was persisting HSIL cytology. Women were in-
vited for a physician-taken cytology sample and a colposcopy 
with biopsies when indicated every 6 months for 2 years. At 
the exit visit, a biopsy was taken in all women to collect a 
histological endpoint. All women enrolled before April 2014 
were eligible for the present study. The study was approved 
by the medical ethical board of Hospital Clínic and signed 
informed consent was obtained from all women. This study is 
registered in the Dutch Trial register (NTR3464).
2.2 | Collection of cervical cytology samples, 
hrHPV, and methylation testing
Physician-taken cervical cytology samples were collected 
using a Cervex-Brush (Rovers Medical Devices BV) and 
were rinsed in 20  mL of Thinprep medium (Hologic), be-
fore colposcopy. Samples were stored at room temperature 
for up to 6 months before DNA was isolated for hrHPV test-
ing. An input volume of 250 μL was used to obtain 100 μL 
of eluate with the QIAamp MinElute Virus Spin kit (QIAgen 
Inc). hrHPV detection was performed using the GP5+/6+-
PCR-EIA (Labo Bio-medical Products). The EIA-positive 
GP5+/6+ amplimers were genotyped using a strip-based test 
by the Genotyping kit HPV GP (Labo Bio-medical Products), 
genotyping hrHPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, and 68.
Residual material after HPV testing and cytology was 
concentrated and sent to DDL Diagnostic Laboratory for 
methylation testing.14 DNA was isolated using the MagNA 
Pure 96. The level of amplifiable human DNA was assessed 
using a qPCR of the in-house reference gene RNaseP with 
the phocine herpesvirus as an internal control for the absence 
of PCR-inhibition.15 All samples with a DNA concentration 
of 2.2 ng/µL or higher were subjected to bisulfite conversion 
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using the EZ DNA Methylation kit (Zymo Research). Samples 
with a DNA concentration below the threshold allowing re-
liable methylation testing in a physician-taken sample were 
excluded. Up to 250 ng/45 µL of DNA was used, with 3 µL 
carrier RNA if samples contained less than 100 ng/45 µL. A 
standardized multiplex qMSP, targeting for the promotor re-
gions of FAM19A4 and miR124 (QIAsure Methylation Test, 
Qiagen), was performed on the bisulfite-converted DNA. The 
bisulfite-converted human reference gene beta-actin was in-
cluded in the multiplex to determine the total amount of con-
verted human DNA. Samples were scored methylation-positive 
when at least one of the markers had a target gene/beta-actin 
ratio above the threshold according to the kit insert. Results of 
marker FAM19A4 were also studied individually.
2.3 | Sectioning and HPV 
testing of histology
Histologic samples were fixed in 10% neutral buffered forma-
lin and embedded in paraffin following routine procedures. 
Four-micrometre-sections were obtained for H&E and p16 
staining and these were assessed by an expert local patholo-
gist following morphologic criteria supported by p16 staining 
according to the LAST recommendations.5 This diagnosis 
was used to decide treatment. Diagnoses on the LEEP speci-
mens were made following the same procedure.
Biopsies were recut at DDL Diagnostic Laboratory, 
Rijswijk, The Netherlands according to the sandwich methods, 
producing one 4-µm-thick H&E before slide, two tubes with 
three 8-µm-thick sections for HPV testing, three 4-µm-thick 
slides for immunohistochemistry, a 4-µm-thick H&E after slide, 
and up to three 4-µm-thick back-up slides. Diagnoses based on 
H&E and IHC recut slides were considered as the definitive di-
agnosis. DNA for HPV detection and genotyping was isolated 
using proteinase K isolation and SPF10-PCR-DEIA-LiPA25 
(version 1, Labo Biomedical Products BV). Women for whom 
the worst diagnosis on the local histology slide was more than 
one SIL/CIN grade different from the recut histology slides 
were excluded. This was done as the study histology could not 
be considered a reliable indicator of the lesion on which treat-
ment was based. Those whose biopsy was hrHPV-negative by 
SPF10-PCR-DEIA-LiPA25v1 were also excluded.
2.4 | p16 and E4 immunohistochemistry 
on biopsies
The biopsy with the worst diagnosis was then stained for p16, 
using p16INK4a antibody (Roche, CINtec®, Clone E6H4™) 
and panHPVE4 mAb (LBP, Clone FH1.1), respectively, after 
heat-induced epitope retrieval with citrate buffer. Reactivity 
was visualized using the EnVision Detection System.
Two expert pathologists, blinded to the local histological 
diagnosis, were asked to score the worst lesion for E4 and p16. 
Biomarker p16 was scored negative (0) when no staining or 
patchy staining was observed, diffuse staining restricted to 
the lower third of the epithelium was scored as 1, staining re-
stricted to the lower two third of the epithelium was scored as 2 
and staining above the lower third of the epithelium, including 
full thickness staining, was scored as 3. E4 staining was scored 
negative (0), focal when limited positive staining was seen in 
the superficial layer of the epithelium (1) or extensive when 
there was widespread-positive staining in the superficial layer 
of the epithelium and or below (2). This grading system has 
been previously validated as reproducible.9,16 p16 score  ≥1 
and E4 score  ≥1 were considered positive scores for these 
markers.
To investigate further the relation between the expression 
of p16 and E4 and outcome we combined scores of p16 and 
E4, and used this to predict the presence of  ≥HSIL/CIN2 
and ≥HSIL/CIN3 on LEEP treatment. Lesions with p16 ex-
pression restricted to the lower third of the epithelium, or 
less, and all lesions with E4 positivity regardless of p16 ex-
pression were classified as combined IHC negative. In line 
with the LAST recommendations, all biopsies expressing p16 
above the lower third of the epithelium,5 and no E4 were con-
sidered combined IHC positive.
2.5 | Statistical analysis
Results were analyzed using IBM SPSS version 22.0 for 
Windows. The level of statistical significance was set at 
P  ≤  .05 for all tests. Agreement between the diagnosis on 
the locally produced slide and the consensus diagnosis on 
the final selection of samples was calculated using Cohen's 
kappa. Correlation coefficients for HPV E4 positivity and 
methylation positivity were calculated using Spearman's cor-
relation test and differences in positivity percentages were 
calculated using the Chi-squared test. The authors confirm 
that the data supporting the findings of this study are avail-
able within the article.
3 |  RESULTS
A total of 538 women had a smear which was eligible for 
methylation testing and interpretation of the result.14 Of 
these women, 482 remained after exclusion of biopsies 
which had a worst diagnosis on the newly sectioned slide 
which was more than 1 grade aside from the consensus di-
agnosis on the locally produced histology slide. Exclusion 
of hrHPV-negative biopsies (87.2% histologically negative 
biopsies) resulted in a selection of 318 women who met the 
inclusion criteria.
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The definitive diagnoses on the recut biopsy used for new 
H&E and IHC slides were as follows: 90 no CIN (28.3%), 67 
LSIL/CIN1 (21.1%), 95 HSIL/CIN2 (29.9%), 62 HSIL/CIN3 
(19.5%), 4 cervical carcinomas (CC) (1.2%). The agreement 
between the diagnosis on the locally produced slide and the 
consensus diagnosis on the newly sectioned slide was sub-
stantial (Cohen's kappa = 0.747).
3.1 | Hypermethylation of FAM19A4 and/or 
miR124-2 on cytology sample
The methylation positivity for markers FAM19A4 individu-
ally and combined with miR124-2, in the cytology samples 
of these women according to the definitive histological diag-
nosis are shown in Table 1. Methylation positivity for mark-
ers FAM19A4 and miR124-2 increased with the severity of 
the lesion: 23.2% of women with no CIN biopsies were posi-
tive for one or more markers compared with 66.1% of women 
with HSIL/CIN3 biopsies.
FAM19A4 was more frequently positive than miR124-2 in 
both ≤LSIL/CIN1 (23.6%, 37/157 compared to 8.9%, 14/157 
for miR124-2, P  <  .001), and in  ≥  HSIL/CIN2 (54.7%, 
88/161 compared to 37.9%, 61/161 for miR124-2, P < .001).
3.2 | Expression of p16 and HPV E4 on 
colposcopic biopsy
The grades of p16 positivity and HPV E4 positivity by worst 
SIL/CIN grade on the worst histological lesion found on col-
poscopy-directed biopsy are shown in Table 2. p16 grade in-
creased with the severity of the lesion, with 85 of 90 (94.4%) 
no CIN biopsies showing no or patchy p16 staining and all 
HSIL/CIN3 lesions showing p16 in at least the lower two third 
of the epithelium or above. None of the no CIN biopsies and 
only 2 of 64 (3.1%) HSIL/CIN3 and none of the ICC showed 
any E4 positivity, while 27 of 67 (40.3%) LSIL/CIN1 and 21 
of 95 (22.1%) HSIL/CIN2 were E4 positive. The highest per-
centage of E4 positivity was found among lesions with p16 
expression in the lower two third of the epithelium (p16 score 
2; 37.3%; 22/59), containing 44.0% (22/50) of all E4-positive 
lesions.
3.3 | Relation between p16 and E4, and 
p16 and methylation
Figure 1 shows the relation between p16 grade of worst le-
sion on colposcopy-directed biopsy, methylation of markers 
FAM19A4 and miR124-2 as detected on cytology sample 
and E4 grade of worst lesion on biopsy.
Expression of E4 increased with increasing p16 expres-
sion with the highest percentage of E4 positivity seen in 
lesions with p16 in the lower two third of the epithelium 
(37.3%). However, in lesions that express p16 above the 
lower two third of the epithelium, E4 positivity dropped to 
10.1% (P < .001). In biopsies showing p16 up to two third 
of the epithelium (n = 189), there was a significant correla-
tion between p16 expression and E4 expression (r = 0.378, 
P < .001).
Of the women with lesions showing no or patchy p16 ex-
pression, 26.2% (27/103) had a FAM19A4 and/or miR124-2 
methylation-positive cytology sample. The frequency 
dropped to 18.5% methylation-positive cytology samples in 
women with lesions showing p16 in the lower third of the 
epithelium but increased to 42.4% methylation positivity 
in women with p16 in the lower two third of the lesion and 
54.3% in women with lesions showing p16 above the lower 
two third of the epithelium. There was a significant correla-
tion between grade of p16 expression on biopsy and meth-
ylation positivity on cytology sample (r = 0.261, P < .001).
3.4 | Relation between methylation and p16/
E4 expression in ≥LSIL/CIN1 lesions
The relation between hypermethylation of markers 
FAM19A4 and/or miR124-2 on cytology sampling and E4/
p16 on the worst histological lesion on biopsy was explored 
by selecting all LSIL/CIN1-3 lesions and ICCs with diffuse 
p16 expression in at least the lower third of the epithelium 
(n = 210). In this group, an inverse relation was found be-
tween E4 and FAM19A4/miR124-2. Figure 2 shows the posi-
tivity for marker FAM19A4 as a single marker and combined 
with (and/or) miR124-2 in E4-negative and E4-positive le-
sions. Of the biopsies negative for HPV E4, 52.1% belonged 
to women with cytology samples positive for methylation 
Diagnosis (N) FAM19A4-positive (%)
FAM19A4 and/or 
miR124-2-positive (%)
Negative (90) 20 (22.2) 21 (23.2)
LSIL/CIN1 (67) 17 (25.4) 17 (25.4)
HSIL/CIN2 (95) 43 (45.3) 44 (46.3)
HSIL/CIN3 (62) 41 (66.1) 41 (66.1)
CC (4) 4 (100) 4 (100)
T A B L E  1  Hypermethylation of single 
marker FAM19A4, and FAM19A4 and 
miR124-2 combined in cytology samples 
related to different histological grades of 
CIN (N = 318)
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marker FAM19A4, which was a significantly higher per-
centage than the 27.9% of women with E4-positive biopsies 
who had a cytology sample positive for methylation marker 
FAM19A4 (P =  .005). The same pattern was observed for 
the combination of FAM19A4 and/or miR124-2 methylation 
markers, which was positive in 52.1% of the women with E4-
negative biopsies and 30.2% of the women with E4-positive 
biopsies (P = .010).
3.5 | Relation of p16/E4 status of worst 
colposcopic biopsy lesion and methylation 
status to detection of ≥HSIL/CIN2 on 
LEEP treatment
To find out the relation between p16/E4 marker patterns on 
colposcopy-directed biopsy or FAM/miR on the cytology 
sample and a ≥HSIL/CIN2 diagnosis on LEEP, 119 women 
with HSIL/CIN2-3 on biopsy treated by LEEP were inves-
tigated. Of these women, 22 (18.5%) with a mean age of 
40.1y had a worst diagnosis of ≤LSIL/CIN1 on LEEP, and 
97 (81.5%) women with a mean age of 37.5y had a worst 
diagnosis of ≥HSIL/CIN2 on LEEP.
Table 3 shows the relation between biopsy diagnosis, worst 
diagnosis on LEEP specimen, and p16/E4 on biopsy and meth-
ylation positivity on cytology sample. Of the treated ≥HSIL/
CIN2 lesions, 17 (14.3%) were E4 positive and 102 (85.7%) 
were E4 negative. However, grade of p16 expression in rela-
tion to E4 expression was important. Lesions with p16 expres-
sion restricted to the lower third of the epithelium, or less, and 
all lesions with E4 positivity were classified as combined IHC 
negative. All biopsies expressing p16 in at least the lower two 
third of the epithelium and no E4 were considered combined 
IHC positive. Of the combined IHC-negative lesions on bi-
opsy, 65.2% (15/23) were confirmed as ≥HSIL/CIN2 lesions 
on LEEP, and 85.4% (82/96) combined IHC-positive lesions 
on biopsy were ≥HSIL/CIN2 on LEEP (P = .025). The same 
was done for the outcome of ≥HSIL/CIN3 on LEEP, show-
ing that 26.1% (6/23) of women with combined IHC-negative 
biopsies and 49.0% (47/96) of women with combined IHC-
positive biopsies had ≥HSIL/CIN3 on LEEP (P = .047).
Of the 119 women who were treated after a  ≥HSIL/
CIN2 lesion on biopsy, 60.5% (72/119) had a FAM and/or 
miR methylation-positive sample and 39.5% (47/119) had 
a methylation-negative sample. ≥HSIL/CIN2 on LEEP oc-
curred in 84.7% (61/72) methylation-positive women and 
76.6% (36/47) methylation-negative women (P  =  .264). 
Among the methylation-negative women there were 34.0% 
(16/47) with ≥HSIL/CIN3 on LEEP (all HSIL/CIN3), and 
among women with methylation-positive samples there 
were 51.4% (37/72) with  ≥HSIL/CIN3 (including two 
CCs; P = .063).
T A B L E  2  p16 and E4 expression in different grades of CIN (n = 318) on worst histological lesion on colposcopy-directed biopsy
p16
Diagnosis
No CIN (N = 90)
LSIL/CIN1 
(N = 67)
HSIL/CIN2 
(N = 95)
HSIL/CIN3 
(N = 62) CC (N = 4)
E4 positive E4 positive E4 positive E4 positive E4 positive
0 - negative (N = 103) 0/85 (0%) 7/15 (47%) 0/3 (0%) 0/0 (0%) 0/0 (0%)
1 - lower 1/3 (N = 27) 0/2 (0%) 7/20 (35%) 1/5 (20%) 0/0 (0%) 0/0 (0%)
2 - lower 2/3 (N = 59) 0/3 (0%) 7/15 (47%) 13/27 (48%) 2/14 (14%) 0/0 (0%)
3 ->lower 2/3 (N = 129) 0/0 (0%) 6/17 (35%) 7/60 (12%) 0/48 (0%) 0/4 (0%)
F I G U R E  1  E4 positivity on biopsy 
(Negative-ICC) and methylation positivity 
on cytology sample (FAM19A4 and/
or miR124-2) in women with lesions 
expressing different grades of p16
6.8%
29.6%
37.3%
10.1%
26.2%
18.5%
42.4%
54.3%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
0 - negave 1 - lower 1/3 2 - lower 2/3 3 - >lower 2/3-full
thickness
E4 posive FAM and/or miR posive
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4 |  DISCUSSION
This study shows that in women who have hrHPV-positive 
SIL/CIN there are complex relationships between expression 
patterns of the widely used immunohistochemical marker p16 
and novel immunohistochemical marker E4 on biopsy. They 
also show relationships between these biopsy markers and 
the methylation markers FAM19A4/miR124-2 on cervical 
cytology sample. Firstly, there is an inverse relation between 
productive infection as shown by HPV E4 positivity in the 
worst lesion present on biopsy, and methylation of markers 
FAM19A4 and miR124-2 on cytology which are associated 
with transforming HPV infection. In women with diffusely 
p16 positive ≥LSIL/CIN1, a difference in FAM19A4 and/or 
miR124-2 positivity rates was found between women with le-
sions expressing E4 and those who did not: 52.1% of women 
with E4-negative and 30.2% with E4-positive biopsies were 
positive for the methylation markers (P = .010).
These results are consistent with previous studies on se-
lective series of expression of somatic tumor suppressor gene 
methylation markers and IHC for p16 and E4 and extend the 
observations to women attending routine colposcopy for an 
abnormal cervical cytology sample.17 Van Zummeren et al 
found an inverse relation between HPV E4 expression and 
methylation positivity for marker combination CADM1/
MAL/miR124-2 detected on biopsy.
In addition, previous work showed that a cumulative im-
munoscore of p16 and Ki-67 improved accuracy and reproduc-
ibility of CIN grading compared to current practice.18 These 
studies and the present study showed that whereas CC shows 
no E4 expression and often expresses both p16 and methyla-
tion marker positivity, LSIL/CIN1 and HSIL/CIN2 are very 
heterogeneous and complex groups, consisting of productive 
infections expressing E4 and transforming lesions expressing 
variable p16, some of which show methylation marker positiv-
ity. The use of the E4 immunomarker and methylation markers 
in this group could offer more detailed information beyond 
current SIL/CIN grading practice and the use of p16 alone.
E4 positivity was related to p16 positivity and histology 
in hrHPV-positive biopsies in a rather complex way. E4 was 
absent in no CIN biopsies, was 40% in LSIL/CIN1, decreased 
to 22% in HSIL/CIN2 and 3% in HSIL/CIN3, and was again 
absent in cancer. The rate of E4 positivity increased with 
grade of p16 expression (r = 0.378) up to 37% in lesions with 
p16 in the lower two third of the epithelium, but fell to 10% 
when p16 expression was above two third of the epithelium.
Hypermethylation of FAM19A4 and/or miR124-2 on cer-
vical cytology sample increased with the grade of SIL/CIN, 
F I G U R E  2  Positivity for marker 
FAM19A4 and markers FAM19A4 and 
miR124-2 combined (and/or) in cytology 
samples, in E4 negative and E4 positive 
LSIL/CIN1 lesions with diffuse p16 
expression in at least the lower 1/3 of the 
epithelium (p16 ≥ 1)
52.1%
27.9%
52.1%
30.2%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
E4 negave E4 posive
FAM19A4 Posive FAM19A4 and/or miR124-2 Posive
T A B L E  3  Women treated after HSIL/CIN2-3 on biopsy (N = 119) and the relation to p16/E4 positivity on biopsy, methylation positivity 
(FAM19A4 and/or miR124-2) on cytology sample and worst diagnosis on LEEP
Worst diagnosis of CIN2/3 on biopsy (n)
Worst diagnosis LEEP
P-
value
Worst diagnosis LEEP
P-value
≤LSIL/
CIN1 ≥HSIL/CIN2 ≤HSIL/CIN2 ≥HSIL/CIN3
Count (%) Count (%) Count (%) Count (%)
Combined IHC 
on biopsy
Combined IHC negative (23) 8 (34.8) 15 (65.2) .025 17 (73.9) 6 (26.1) .047
Combined IHC positive (96) 14 (14.6) 82 (85.4) 49 (51.0) 47 (49.0)
Methylation on 
cytology
Methylation negative (47) 11 (23.4) 36 (76.6) .264 31 (66.0) 16 (34.0) .063
Methylation positive (72) 11 (15.3) 61 (84.7) 35 (48.6) 37 (51.4)
Note: Lesions with p16 expression restricted to the lower third of the epithelium, or less, and all lesions with E4 positivity regardless of p16 expression were classified 
as combined IHC negative. All biopsies expressing p16 in at least the lower two third of the epithelium and no E4 were considered combined IHC positive.
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but there was some positivity (24%) in ≤LSIL/CIN1, rising to 
66% in HSIL/CIN3 and was seen in all cancers. Methylation 
positivity progressively increased with grade of diffuse p16 
positivity (18.5% in lesions with p16 in the lower third to 
54.3% in lesions with p16 up to full thickness). There was 
also some (26.2%) methylation in samples of women with 
lesions negative or patchy for p16 IHC.
p16 is widely used as marker of transformation in hrH-
PV-associated CC and precancer, but this study shows that it is 
also expressed in up to the lower two third of cervical epithe-
lium in lesions showing completion of the HPV life cycle and 
HPV production by E4 expression, and that increasing extent 
of p16 expression up to two third of the epithelium is associ-
ated with more frequent E4 expression. This is consistent with 
the expression of p16 as a surrogate for hrHPV E7 expression 
and the important role of E7 in driving the increased epithelial 
proliferation above the basal layer necessary for viral repro-
duction, as well as playing a part in driving neoplastic trans-
formation. This finding explains the difficulty of using p16 on 
its own as a reliable transformation marker in SIL/CIN diag-
nosis. Only expression of p16 above two third of the epithe-
lium is associated with infrequent E4 expression showing loss 
of viral life cycle completion with virus production and in-
creased frequency of methylation of tumor suppressor genes.
We also found evidence that p16 expression and E4 posi-
tivity on the worst colposcopy-directed biopsy related to the 
frequency of finding HSIL/CIN2 and HSIL/CIN3 on LEEP 
in women treated for ≥HSIL/CIN2. Our results support the 
view that lesions with diffuse p16 expression limited to the 
basal third and E4 positivity are likely to be smaller and/
or more regressive lesions. Luttmer et al have previously 
shown an increasing positivity rate for FAM19A4 analysis 
performed on cervicovaginal self-samples and cervical cy-
tology samples with the severity and volume of the lesion.19 
In the present study, a methylation-positive cytology sample 
showed no significant relation to treatment outcome.
This study was performed in a selected group of women 
who were referred for colposcopic examination after an ab-
normal Pap-smear result, who had a hrHPV-positive cervical 
biopsy and had cervical cytology samples suitable for methyla-
tion testing. Methylation status was only determined in the cer-
vical cytology samples and not on biopsy. However, a previous 
study from van Baars et al confirmed that the methylation sta-
tus of the cervical cytology sample represents the methylation 
status of the worst lesion present on the cervix when taking bi-
opsies of all lesions detected during colposcopy together with 
a random biopsy of normal appearing tissue.9 Sensitivity of 
colposcopy for the detection of ≥HSIL/CIN2 is between 50% 
and 70%20-23 and methylation positivity on cytology in the ab-
sence of high-grade disease on biopsy could possibly originate 
from a high-grade lesion that was missed on colposcopy.
We used a reference standard diagnosis in which the opin-
ion of at least three pathologists was reflected, and which 
assured that the worst lesion was present in all tested ma-
terial. It is known that reproducibility of diagnosis of LSIL/
CIN1 and HSIL/CIN2 is limited and intra- and interobserver 
agreement is moderate.5,24 By excluding women in which the 
SIL/CIN colposcopy-directed biopsy diagnosis of the worst 
lesion on the newly produced slide differed more than one 
histological grade from the consensus diagnosis on the local 
slide, we attempted to use the most accurate reference stan-
dard diagnosis as possible, still allowing for biomarker ex-
pression identification.
Large prospective studies are needed to investigate the out-
come of E4-positive and negative LSIL/CIN1 and HSIL/CIN2. 
Currently available methylation markers have shown good 
clinical performance in the detection of advanced transforming 
precursor lesions and CC in hrHPV-positive women. In addi-
tion, results from a large follow-up study have shown a low CC 
risk for hrHPV-positive women with a negative FAM19A4/
miR124-2 triage test result, offering an objective triage test in 
hrHPV-based screening programs.25 We found that FAM19A4 
has the major contribution to predicting the presence of HSIL/
CIN3 as compared to miR124-2. We scored methylation mark-
ers positive or negative, without taking into account the hyper-
methylation levels. Studies on tumor suppressor genes CADM1 
and MAL showed increasing levels of hypermethylation to-
ward CC.11 Future studies are needed to demonstrate whether 
FAM19A4 and miR124-2 methylation positivity levels differ 
between women with E4-positive and E4-negative lesions.
Our results show that there is a possibility of more spe-
cific diagnosis of CIN when using grading of patterns of 
immunohistochemical expression of HPV E4 in combina-
tion with p16INK4A. Lesions with diffuse, but limited p16 
positivity and E4 positivity most likely represent early 
transforming and productive lesions with variable HPV 
life cycle completion and might have a higher probability 
of spontaneous regression. Extensively p16-positive, E4-
negative lesions in patients, and those with a methylation 
positive cervical cytology sample are more often ≥HSIL/
CIN3 lesions and most likely represent advanced transform-
ing lesions that require LEEP treatment. Further studies are 
required to establish the progression risk of different bio-
marker expression patterns in women not treated by LEEP.
ACKNOWLEDGMENTS
The authors thank Nadia Abu-Lhiga, Agata Rodriguez and 
Inma Nicolas, Hospital Clínic for their clinical assistance. 
They thank Lorena Marimon and Esther Barnadas, Hospital 
Clínic, and Laura van der Hoeven, Ingrid Poot, Peter Lanser 
and Henk van den Munckhof, DDL Diagnostic Laboratory, 
for their technical assistance. They also thank Miekel van 
de Sandt, DDL Diagnostic Laboratory, and Frank Smedts, 
Reinier de Graaf Gasthuis, for reviewing the biopsy diagno-
ses. Finally, they wish to thank all clinical and laboratory per-
sonnel and all women who participated in the study.
8 |   LEEMAN Et AL.
DATA AVAILABILITY STATEMENT
The authors confirm that the data supporting the findings of 
this study are available within the article.
ORCID
Annemiek Leeman   https://orcid.
org/0000-0002-5882-7778 
Marta del Pino   https://orcid.org/0000-0003-2178-2403 
REFERENCES
 1. Stoler MH, Schiffman M, Atypical Squamous Cells of 
Undetermined Significance-Low-grade Squamous Intraepithelial 
Lesion Triage Study G. Interobserver reproducibility of cervical 
cytologic and histologic interpretations: realistic estimates from 
the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500-1505.
 2. McAllum B, Sykes PH, Sadler L, Macnab H, Simcock BJ, Mekhail 
AK. Is the treatment of CIN 2 always necessary in women under 25 
years old? Am J Obstet Gynecol. 2011;205(5):478.e1-478.e7.
 3. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cer-
vical neoplasia and risk of invasive cancer in women with cervi-
cal intraepithelial neoplasia 3: a retrospective cohort study. Lancet 
Oncol. 2008;9:425-434.
 4. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical 
implications of (epi)genetic changes in HPV-induced cervical pre-
cancerous lesions. Nat Rev Cancer. 2014;14:395-405.
 5. Darragh TM, Colgan TJ, Cox JT, et al. The lower anogenital squa-
mous terminology standardization project for HPV-associated le-
sions: background and consensus recommendations from the College 
of American Pathologists and the American Society for Colposcopy 
and Cervical Pathology. J Low Genit Tract Dis. 2012;16:205-242.
 6. Doorbar J. The E4 protein; structure, function and patterns of ex-
pression. Virology. 2013;445:80-98.
 7. Griffin H, Soneji Y, Van Baars R, et al. Stratification of HPV-
induced cervical pathology using the virally encoded molec-
ular marker E4 in combination with p16 or MCM. Mod Pathol. 
2015;28:977-993.
 8. Leeman A, Pirog EC, Doorbar J, et al. Presence or absence of 
significant HPVE4 expression in high-grade anal intraepi-
thelial neoplasia with p16/Ki-67 positivity indicates distinct 
patterns of neoplasia: a study combining immunohistochemis-
try and laser capture microdissection PCR. Am J Surg Pathol. 
2018;42:463-471.
 9. van Baars R, Griffin H, Wu Z, et al. Investigating diagnostic prob-
lems of CIN1 and CIN2 associated with high-risk HPV by com-
bining the novel molecular biomarker PanHPVE4 with P16INK4a. 
Am J Surg Pathol. 2015;39:1518-1528.
 10. Verlaat W, Van Leeuwen RW, Novianti PW, et al. Host-cell DNA 
methylation patterns during high-risk HPV-induced carcinogenesis 
reveal a heterogeneous nature of cervical pre-cancer. Epigenetics. 
2018;13:769-778.
 11. Bierkens M, Hesselink AT, Meijer CJ, et al. CADM1 and MAL 
promoter methylation levels in hrHPV-positive cervical scrapes in-
crease proportional to degree and duration of underlying cervical 
disease. Int J Cancer. 2013;133:1293-1299.
 12. De Strooper LM, Meijer CJ, Berkhof J, et al. Methylation analysis 
of the FAM19A4 gene in cervical scrapes is highly efficient in de-
tecting cervical carcinomas and advanced CIN2/3 lesions. Cancer 
Prev Res (Phila). 2014;7:1251-1257.
 13. van der Marel J, van Baars R, Quint WG, et al. The impact of 
human papillomavirus genotype on colposcopic appearance: a 
cross-sectional analysis. BJOG. 2014;121:1117-1126.
 14. Leeman A, Del Pino M, Marimon L, et al. Reliable identification 
of women with CIN3+ using hrHPV genotyping and methylation 
markers in a cytology-screened referral population. Int J Cancer. 
2019;144:160-168.
 15. Luo W, Yang H, Rathbun K, Pau CP, Ou CY. Detection of human 
immunodeficiency virus type 1 DNA in dried blood spots by a du-
plex real-time PCR assay. J Clin Microbiol. 2005;43:1851-1857.
 16. Dijkstra MG, Heideman DA, de Roy SC, et al. p16(INK4a) immu-
nostaining as an alternative to histology review for reliable grading 
of cervical intraepithelial lesions. J Clin Pathol. 2010;63:972-977.
 17. Zummeren MV, Kremer WW, Leeman A, et al. HPV E4 expres-
sion and DNA hypermethylation of CADM1, MAL, and miR124-2 
genes in cervical cancer and precursor lesions. Mod Pathol. 
2018;31(12):1842-1850.
 18. van Zummeren M, Leeman A, Kremer WW, et al. Three-tiered 
score for Ki-67 and p16(ink4a) improves accuracy and reproduc-
ibility of grading CIN lesions. J Clin Pathol. 2018;71:981-988.
 19. Luttmer R, De Strooper LM, Dijkstra MG, et al. FAM19A4 meth-
ylation analysis in self-samples compared with cervical scrapes 
for detecting cervical (pre)cancer in HPV-positive women. Br J 
Cancer. 2016;115:579-587.
 20. Bekkers RL, van de Nieuwenhof HP, Neesham DE, Hendriks JH, 
Tan J, Quinn MA. Does experience in colposcopy improve identi-
fication of high grade abnormalities? Eur J Obstet Gynecol Reprod 
Biol. 2008;141:75-78.
 21. Massad LS, Jeronimo J, Katki HA, Schiffman M; National 
Institutes of Health/American Society for C, Cervical Pathology 
Research Group. The accuracy of colposcopic grading for detec-
tion of high-grade cervical intraepithelial neoplasia. J Low Genit 
Tract Dis. 2009;13:137-144.
 22. Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, 
Richards-Kortum R. Colposcopy for the diagnosis of squa-
mous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 
1998;91:626-631.
 23. Wentzensen N, Schiffman M, Dunn ST, et al. Grading the severity of 
cervical neoplasia based on combined histopathology, cytopathol-
ogy, and HPV genotype distribution among 1,700 women referred 
to colposcopy in Oklahoma. Int J Cancer. 2009;124:964-969.
 24. Herrington CS. The terminology of pre-invasive cervical le-
sions in the UK cervical screening programme. Cytopathology. 
2015;26:346-350.
 25. De Strooper LMA, Berkhof J, Steenbergen RDM, et al. Cervical 
cancer risk in HPV-positive women after a negative FAM19A4/
mir124-2 methylation test: A post hoc analysis in the POBASCAM 
trial with 14 year follow-up. Int J Cancer. 2018;143:1541-1548.
How to cite this article: Leeman A, Jenkins D, del 
Pino M, et al. Expression of p16 and HPV E4 on 
biopsy samples and methylation of FAM19A4 and 
miR124-2 on cervical cytology samples in the 
classification of cervical squamous intraepithelial 
lesions. Cancer Med. 2020;00:1–8. https ://doi.
org/10.1002/cam4.2855
